Blood Transfusion Utilization in Patients with Severe Coronavirus Disease 2019 in the Republic of Korea: A Nationwide Population-Based Study
Open Access
- 2 December 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7327
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has significantly affected both supply and demand for blood transfusion. This study aimed to investigate the prescription patterns of blood products and identify the risk factors for blood transfusion in patients with severe COVID-19. Methods: This nationwide population-based cohort study was performed in the Republic of Korea between January 2021 and December 2021. Adult patients (≥19 years) with severe COVID-19 who received oxygen therapy were examined. Data were obtained from the National Health Insurance Service database. Results: During the study period, 41,203 patients developed severe COVID-19. The overall transfusion rate was 7.11%, with 14,477 units of packed red blood cells, 4501 units of fresh frozen plasma, 20,532 units of platelet concentrates, and 1875 units of cryoprecipitate. Blood transfusion was independently associated with 90-day mortality (hazard ratio: 1.36, 95% confidence interval: 1.21–1.53, p < 0.001). Multivariate logistic regression analysis identified underlying chronic kidney disease; exposure to surgery, thrombolysis, or thrombectomy; renal replacement therapy; mechanical ventilation; and extracorporeal membrane oxygenation as significant risk factors for blood transfusion in patients with severe COVID-19. Conversely, underlying cerebrovascular diseases, a Charlson Comorbidity Index score of ≥6, admission to intensive care units, and anticoagulant use were identified as protective factors. Conclusions: This study provides an overview of blood transfusion patterns in patients with severe COVID-19. Understanding these patterns may help optimize the stockpiling of medical resources.Keywords
Funding Information
- Korea Health Industry Development Institute (HI22C1463, HI23C1297)
- 4P Lab, Co., Ltd. (HI22C1463, HI23C1297)
This publication has 26 references indexed in Scilit:
- Perioperative transfusion and long-term mortality after cardiac surgery: a meta-analysisGeneral Thoracic and Cardiovascular Surgery, 2023
- Blood Product Utilization in Patients With COVID-19 on ECMOJournal of Surgical Research, 2022
- Clinical characteristics and indications for blood transfusion in patients with SARS-CoV-2 infectionMedicina Clinica, 2021
- Effects of the COVID-19 pandemic on supply and use of blood for transfusionThe Lancet Haematology, 2020
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysisClinica Chimica Acta, 2020
- Endpoints used in phase III randomized controlled trials of treatment options for COVID-19eClinicalMedicine, 2020
- Blood and blood product use during COVID‐19 infectionAmerican Journal of Hematology, 2020
- Coronavirus Disease 2019: Coronaviruses and Blood SafetyTransfusion Medicine Reviews, 2020
- Impact of red blood cell transfusion on acute coronary syndrome: a meta-analysisInternal and Emergency Medicine, 2016